LONDON – In more promising news in the fight against Covid-19, UK drug maker AstraZeneca’s vaccine candidate has received regulatory approval in the United Kingdom

The vaccine was made in collaboration with UKOxford University and comes three weeks after the UK was the first nation to bring the Pfizer BioNTech vaccine to market

The vaccine is believed to be important to the vaccination effort in developing countries because it is cheaper to manufacture and easier to store for long periods of time, as only a normal refrigeration temperature is required to remain viable, making it easier to distribute

It is truly fantastic news – and triumph for UK science – that the vaccine has been approved for use @UniofOxford / @ AstraZeneca We will now try to vaccinate as many people as we can as soon as possible ImageTwittercom / cR4pRdZJlT

“With two vaccines now approved, we can vaccinate more people at the highest risk, protect them from the disease, and reduce mortality and hospitalization,” said The UKsaid the Ministry of Health in a statement

However, the statement noted that social distancing and hand washing are still important to suppress the infection while people across the country await to receive the vaccines

Professor Andrew Pollard, Director of the Oxford Vaccine Group, said, “While this is just the beginning, we will be one step ahead of the pandemic, protecting health and the economy as vulnerable people everywhere are vaccinated, as many as possible soon possible ”

Pascal Soriot, CEO of AstraZeneca, said: “Today is an important day for millions of people in the UK who will have access to this new vaccine. It has been shown to be effective, well tolerated, easy to administer and is being used by AstraZeneca without Profit delivered “

Minister of Health @MattHancock informs @skygillian that the UK has ordered 100 million doses of the Oxford / AstraZeneca vaccine and that it will launch on Aug. January will begin Read more: https: // tco / BqydNJZtMK ImageTwittercom / ghfoeBfkQ6

The UK is in the middle of a serious surge in Covid-19 infections On Tuesday, a record of 53000 confirmed hospitals across the country are filling up with Covid patients for fear that some intensive care units will not be able to handle this

This month, the Oxford vaccine first published its Phase 3 clinical trial results in a peer-reviewed medical journal, the Lancet, which confirmed initial results that the shots had an average effectiveness of 704 percent / p>

Peer-reviewed data that experts were dying to see showed that it was around 11 weeks after the first doses were given600 volunteers in the U did not have hospital admissions or cases of severe Covid-19K and Brazil

Last month, Oxford University researchers released results from their Phase 3 study, including one surprising detail: some of the study volunteers received a lower first dose of the vaccine but appeared to have greater protection – 90 percent – against symptomatic Covid-19 to have

Volunteers who received a standard double dose received around 62 percent protection. The combination of the two gave an average of around 70 percent

However, questions arose after it was discovered that the lower dose was accidentally administered – something the officials and scientists failed to mention when presenting their results

UKThe Department of Health said its priority is giving as many vulnerable people a first dose as possible rather than providing the required two doses in as short a time as possible “

The department added that anyone who receives the vaccination will still have their second dose within 12 weeks of the first to ensure longer-term protection

The AstraZeneca-Oxford team, once considered pioneers in developing a coronavirus vaccine, has been overtaken by Pfizer and its German partner BioNTech, whose recordings were launched in the UK and US this month

The US. The federal government has ordered 300 million doses of the vaccine and pledged up to $ 1 billion to support its research and developmentK has also secured access to 100 million cans, with up to 4 million cans expected to be ready by the end of the year

Another difficulty for vaccine manufacturers is whether their candidate can compete with a new variant of the coronavirus, which was first discovered in England and is now spreading worldwide, making the virus up to 70 percent more contagious

Last week, AstraZeneca said its vaccine against the new variant should be effective, but studies have been done to fully examine the effects of the mutation


World News – GB – UK The regulator grants approval for AstraZeneca’s Covid-19 vaccine